South Korea-based biotechnology company Hyundai Bioscience announced on Wednesday that XAFTY has a strong likelihood of being able to treat Ebola and Hantavirus due to its low IC50 (50% inhibitory concentration) for those viruses.

Amid the current crisis of these two often fatal infectious diseases XAFTY should be considered for testing, the company said.

XAFTY has an IC50 level of 0.28 micrometres against SARS-CoV-2, the pathogen in COVID-19, and has already proven its therapeutic efficacy in human COVID-19 clinical trials.

The IC50 level of XAFTY is even lower for the Ebola virus at 0.125 micrometres, suggesting that XAFTY could be a promising agent to treat Ebola-infected patients.

Additionally, XAFTY has demonstrated inhibitory efficacy of less than 0.125 micrometres against the Severe Fever with Thrombocytopenia Syndrome (SFTS) virus, serving as scientific evidence for activity against Hantavirus. Both SFTS virus and Hantavirus belong to the same virus class.

XAFTY has shown its safety through the COVID-19 Phase 2/3 clinical trials and an ongoing Dengue Phase 2/3 clinical trial in Vietnam, with no severe adverse events reported so far across all dosage groups.

Hyundai Bioscience confirmed that it has enough drug inventory for immediate supply to the outbreak frontlines.